NeoGenomics Reports First Quarter 2024 Results
First Quarter Revenue Increased 14% to $156 Million ...
Stay updated with breaking news from Advanced Diagnostics Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Quarter Revenue Increased 14% to $156 Million ...
Fourth Quarter Revenue Increased 12% to $156 million;Full Year Revenue Increased 16% to $592 millionFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 resul...
Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million ...
NeoGenomics, Inc. (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter...
NeoGenomics Announces the Commercial Availability of Two New Tests, ...